⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Gold Reserve Provides Update on Court Decision in Citgo Sale Process: Delaware District Court Adopts Special Master’s Recommendation of Elliott/Amber Energy $5.9 Billion Bid Over Objections
businesswire.com
XG
SNY
CITGO
8MM Respiratory Syncytial Virus Prophylaxis Drug Forecast Report 2025: A $7.2 Billion Market by 2030, Prophylactic Options to Continue to Diversify Due to Strength of Late-stage Pipeline
globenewswire.com
AZN
ABBV
SNY
MRK
GSK
PFE
MRNA
CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi
globenewswire.com
MRK
SNY
REGN
Hidradenitis Suppurativa Market Opportunity Forecast Report 2025: 7MM Market to Reach $7.8 Billion by 2034, Driven by New Biologics and Small-Molecule Launches Including Sonelokimab and Povorcitinib
globenewswire.com
ABBV
INCY
JNJ
MRK
NVS
SNY
Hyaluronic Acid Market Forecasts Report 2025-2030: Opportunities Driven by Demand for Non-surgical Cosmetic Procedures and Interest in Anti-aging Solutions
globenewswire.com
ABBV
SNY
AKTX
Gold Reserve Provides Update on Court Decision in Citgo Sale Process: Delaware District Court Adopts Special Master’s Recommendation of Elliott/Amber Energy $5.9 Billion Bid Over Objections
businesswire.com
XG
SNY
X
Liver Cancer Drug Market Poised to Reach US$ 17.2 Billion by 2033 Amid Rapid Advances in Targeted Therapies | Astute Analytica
globenewswire.com
BMY
MRK
AZN
ELVN
REGN
GILD
NVS
SNY
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
globenewswire.com
REGN
SNY
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight
globenewswire.com
GSK
TREVI
MRK
AZN
SNY
TEVA
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
globenewswire.com
REGN
SNY